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BACKGROUND & AIMS: There are no effective and safe
treatments for chronic hepatitis C virus (HCV) infection of pa-
tients who have advanced liver disease. METHODS: In this
phase 2, open-label study, we assessed treatment with the
NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor
sofosbuvir, and ribavirin in patients infected with HCV geno-
types 1 or 4. Cohort A enrolled patients with cirrhosis and
moderate or severe hepatic impairment who had not under-
gone liver transplantation. Cohort B enrolled patients who had
undergone liver transplantation: those without cirrhosis; those
with cirrhosis and mild, moderate, or severe hepatic impair-
ment; and those with ﬁbrosing cholestatic hepatitis. Patients
were assigned randomly (1:1) to receive 12 or 24 weeks of a
ﬁxed-dose combination tablet containing ledipasvir and sofos-
buvir, once daily, plus ribavirin. The primary end point was
sustained virologic response at 12 weeks after the end of
treatment (SVR12). RESULTS: We enrolled 337 patients, 332
(99%) with HCV genotype 1 infection and 5 (1%) with HCV
genotype 4 infection. In cohort A (nontransplant), SVR12 wasachieved by 86%–89% of patients. In cohort B (transplant re-
cipients), SVR12 was achieved by 96%–98% of patients
without cirrhosis or with compensated cirrhosis, by 85%88%
of patients with moderate hepatic impairment, by 60%–75% of
patients with severe hepatic impairment, and by all 6 patients
with ﬁbrosing cholestatic hepatitis. Response rates in the
12- and 24-week groups were similar. Thirteen patients (4%)
discontinued the ledipasvir and sofosbuvir combination pre-
maturely because of adverse events; 10 patients died, mainly
from complications related to hepatic decompensation.
CONCLUSION: The combination of ledipasvir, sofosbuvir,
and ribavirin for 12 weeks produced high rates of SVR12 in
patients with advanced liver disease, including those with
decompensated cirrhosis before and after liver transplantation.
ClinTrials.gov: NCT01938430.
CLINICAL
LIVER
650 Charlton et al Gastroenterology Vol. 149, No. 3Keywords: Hepatitis C Virus Infection; Decompensated
Cirrhosis; Liver Transplantation; Fibrosing Cholestatic
Hepatitis.
atients with chronic hepatitis C virus (HCV) infectionPand advanced liver disease—especially patients with
decompensated cirrhosis—have a poor prognosis and
limited treatment options.1,2 Liver failure and hepatocellular
carcinoma related to HCV infection are the most common
indications for liver transplantation in North America and
Europe.3,4 In patients with detectable virus at the time of
transplantation, recurrent HCV infection is universal and
30% of patients have an aggressive clinical and histologic
course with increased morbidity, mortality, and graft loss.5–7
There is an urgent medical need for safe and effective treat-
ments for patients with advanced liver disease. To date, few
clinical trials have included patients with decompensated
liver disease and the effect of sustained virologic response on
liver-related function and outcomes is not known.
Sofosbuvir is a nucleotide analogue inhibitor approved
for the treatment of HCV.8 In phase 2 trials, sofosbuvir plus
ribavirinwas used to treat patients both before and after liver
transplantation, including those with compensated cirrhosis,
with moderate efﬁcacy after prolonged (24–48 wk) admin-
istration.9,10 Sofosbuvir plus ribavirin also has been used
successfully in a subgroup of patients with decompensated
cirrhosis in a compassionate-use program, with similarly
moderate efﬁcacy.11 A ﬁxed-dose combination of sofosbuvir
with the HCV NS5A inhibitor ledipasvir recently was
approved in the United States and Europe for the treatment of
chronic genotype 1 HCV infection.12 The safety and efﬁcacy of
ledipasvir-sofosbuvir among patients with compensated
cirrhosis has been established,13 but this combination has not
been evaluated previously in patients with more advanced
liver disease. We conducted an open-label, phase 2 study to
determine the efﬁcacy and safety of ledipasvir-sofosbuvir
with ribavirin in patients with advanced liver disease,
including patients who have undergone liver transplantation.
Materials and Methods
Patients
Between September 6, 2013, and January 11, 2014, patients
were enrolled at 29 clinical sites in the United States. Eligible
patients were at least 18 years of age and chronically infected
with genotypes 1 or 4 HCV. Patients co-infected with human
immunodeﬁciency virus or hepatitis B virus or with prior
exposure to an NS5a inhibitor were not eligible for enrollment.
Patients with any of the following laboratory abnormalities also
were excluded from enrollment: hemoglobin level less than 10
g/dL, platelet level of 30,000/mm3 or less, alanine amino-
transferase, aspartate aminotransferase, or alkaline phospha-
tase level 10 times or more the upper limit of normal, total
bilirubin level greater than 10 mg/dL (except for the ﬁbrosing
cholestatic hepatitis [FCH] cohort), serum creatinine level
greater than 2.5 times the upper limit of normal, and/or evi-
dence of renal impairment (creatinine clearance, <40 mL/min).
Patients were enrolled in 2 cohorts. Cohort A consisted of 2
groups of patients with advanced cirrhosis (Child–Pugh class Band C, Supplementary Table 1) caused by chronic HCV infection
who had not undergone liver transplantation: group 1 enrolled
patients with cirrhosis and moderate hepatic impairment
(Child–Pugh class B), and group 2 enrolled patientswith cirrhosis
and severe hepatic impairment (Child–Pugh class C). Cohort B
consisted of 5 groups of patients, all ofwhomhadundergone liver
transplantation previously: group 3 enrolled patients without
cirrhosis, group 4 enrolled patients with compensated cirrhosis
and mild hepatic impairment (Child–Pugh class A), group 5
enrolled patients with cirrhosis and moderate hepatic impair-
ment (Child–Pugh class B), group 6 enrolled patients with
cirrhosis and severe hepatic impairment (Child–Pugh class C),
and Supplementary group 7 enrolled patients with ﬁbrosing
cholestatic hepatitis (Supplementary Appendix).Study Design
In this open-label, phase 2 study, patients in each of the 7
groups were randomized using a computer-generated
randomization sequence generated by Bracket (San Francisco,
CA) and allocated by means of an interactive web response
system in a 1:1 ratio to receive either 12 or 24 weeks of
treatment with ledipasvir 90 mg and sofosbuvir 400 mg in a
ﬁxed-dose combination tablet (ledipasvir-sofosbuvir) once
daily plus ribavirin. For groups 3, 4, and 7, ribavirin was
administered orally twice daily, with the dose determined ac-
cording to body weight (1000 mg/day in patients with a body
weight of <75 kg, and 1200 mg/day in patients with a body
weight 75 kg). For groups 1, 2, 5, and 6, ribavirin was
administered at a starting dose of 600 mg in a divided daily
dose. Provided that the starting dose was well tolerated, and
that hemoglobin levels remained higher than 10 g/dL without
hematologic growth factor support, the dose could be increased
to a maximum of 1000 mg/day in patients with a body weight
of less than 75 kg, and 1200 mg/day in patients with a body
weight of 75 kg or greater. For patients who could not tolerate
the starting dose of 600 mg, the dose was reduced as necessary
on the basis of hemoglobin levels or other ribavirin side effects.
Management of immunosuppression was not speciﬁed in
the clinical protocol, but levels and resulting dose adjustments
were recorded to assess whether the regimens required an
adjustment in correlation with resolution of HCV infection or
because of drug interaction with study treatment.Study Assessments
Serum HCV-RNA level was measured using the Roche
(Branchburg, NJ) COBAS AmpliPrep/COBAS TaqMan HCV Test,
v2.0 (HCV RNA polymerase chain reaction). HCV genotype and
subtype were determined using the Siemens (Tarrytown, NY)
Versant HCV Genotype INNO-LiPA 2.0 Assay, the Trugene HCV
5’NC Genotyping Assay, and NS5b sequencing. The interleukin
28B genotype was determined by polymerase chain reaction
ampliﬁcationof the single-nucleotidepolymorphismrs12979860.
For analysis of viral resistance, we collected samples at
baseline from all patients. The HCV NS5A and NS5B coding
regions were ampliﬁed using standard reverse-transcription
polymerase chain reaction technology. Variants present at
more 1% of sequence reads are reported. For patients who had
virologic failure, deep sequencing was performed for the HCV
NS5A and NS5B coding regions with samples collected at the
ﬁrst virologic failure time point. Variants in NS5A and NS5B
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were compared with the respective baseline sequence.
End Points and Statistical Analysis
The primary efﬁcacy end point was the rate of sustained
virologic response, deﬁned as the absence of quantiﬁable HCV
RNA in serum (<15 IU/mL) at 12 weeks after the end of
therapy (SVR12) among all patients who underwent randomi-
zation and received at least 1 dose of study drugs. The pro-
portions of patients with SVR12 along with a 2-sided 90%
conﬁdence interval (using the Clopper–Pearson method) were
calculated by group and treatment duration. We did not
perform a formal sample size calculation. The enrolment target
of 50 patients for all groups (except group 3, which had an
enrolment target of 100 patients) was chosen to provide a
reasonable estimate of SVR12 with appropriate 90% conﬁ-
dence intervals. The efﬁcacy end point for patients who un-
derwent liver transplantation during the study was the rate of
post-transplant virologic response (deﬁned as HCV-RNA level
<15 IU/mL at 12 weeks after transplant) in all patients who
have HCV-RNA level less than 15 IU/mL at their last observed
HCV RNA quantiﬁcation before transplantation. Six of these
patients underwent liver transplantation with HCV-RNA level
less than 15 IU/mL before post-treatment week 12 and were
not included in the efﬁcacy analysis for cohort A. The primary
safety end point was the proportion of patients who dis-
continued study treatment owing to an adverse event. Sec-
ondary end points included improvements in Child–Pugh class
and model for end-stage liver disease (MELD) score during
treatment and follow-up evaluation. We used the Wilcoxon
rank sum test to analyze the bilirubin and albumin data.
Study Oversight
The design of this study, which was in compliance with the
principles of the Declaration of Helsinki, Good Clinical Practice
guidelines, and local regulatory requirements, was approved by
the institutional review board or independent ethics committee
at each participating site. This study was conducted according
to the protocol by the sponsor (Gilead Sciences) in collabora-
tion with the academic investigators.
Role of the Funding Source
The sponsor collected the data, monitored the study
conduct, and performed the statistical analyses. An independent
data and safety monitoring committee reviewed the progress of
the study. The investigators, participating institutions, and
sponsor agreed to maintain conﬁdentiality of the data. All the
authors had access to the data and assume responsibility for the
integrity and completeness of the data and analyses reported.
The ﬁrst draft of the manuscript was prepared by a professional
writer who is an employee of Gilead Sciences and both corre-
sponding authors, with input from all the authors.Results
Patient Baseline Characteristics
Of the 417 patients screened, 337 were enrolled, 332
(99%) with HCV genotype 1 infection and 5 (1%) with HCV
genotype 4 infection (Supplementary Table 2 in theSupplementary Appendix). Only 9 patients were enrolled in
group 6 (patients with Child–Pugh class C liver disease who
had undergone liver transplantation) and only 6 patientswere
enrolled in group 7 (patients with ﬁbrosing cholestatic hepa-
titis). The demographic and baseline clinical characteristics of
the patients generally were balanced between the 12- and 24-
week treatment arms in each of the 7 patient groups (Table 1).
Seven patients in cohort A underwent liver trans-
plantation, 4 patients during study treatment and 3 patients
after completing study treatment (Figure 1).
Efﬁcacy
Nontransplanted Patients With Decompensated
Cirrhosis: Groups 1 and 2. Rates of sustained virologic
response among patients with Child–Pugh class B disease
who had not undergone transplantation were similar
regardless of treatment duration: 87% in patients who
received 12 weeks of treatment and 89% in patients who
received 24 weeks of treatment (Table 2 and
Supplementary Table 3). Rates of sustained virologic
response also were similar among patients with Child–Pugh
class C decompensated disease who had not undergone
transplantation regardless of treatment: 86% and 87% in
patients who received 12 and 24 weeks of treatment,
respectively (Supplementary Table 4).
In the majority of patients with Child–Pugh class B and C
disease, MELD and Child–Pugh–Turcotte (CPT) scores
decreased between baseline and post-treatment week 4
(Figure 2, Supplementary Figures 2–5, and Supplementary
Table 5). Patients with Child–Pugh class B disease had sta-
tistically signiﬁcant improvements from baseline in total
bilirubin and albumin levels from baseline to post-treatment
week 4 (Supplementary Appendix, Supplementary Table 5).
Post-Transplant Patients With No Cirrhosis or
Compensated Cirrhosis: Groups 3 and 4. Among pa-
tients with no cirrhosis or compensated cirrhosis who had
undergone liver transplantation, rates of sustained virologic
response ranged from 96% to 98%. Rates of response in
these groups did not substantially vary by the presence or
absence of cirrhosis or by treatment duration (Table 2).
Post-Transplant Patients With Decompensated
Cirrhosis: Groups 5 and 6. Rates of sustained virologic
response among patients with Child–Pugh class B disease
who had undergone liver transplantation were similar
regardless of treatment duration: 86% in those who
received 12 weeks of treatment and 88% in those who
received 24 weeks of treatment. Patients with Child–Pugh
class C disease who had undergone transplantation (group
6) had lower rates of sustained virologic response (60% and
75%, respectively, in patients receiving 12 and 24 weeks of
treatment), but the small number of patients enrolled in this
group (n ¼ 9) makes this result difﬁcult to interpret. Similar
to nontransplanted patients, the majority of patients with
both Child–Pugh class B and C disease who had undergone
liver transplantation had MELD and CPT scores that were
improved at post-treatment week 4 compared with baseline
levels (Figure 1 and Supplementary Figure 2).
FCH: Group 7. All 6 patients with ﬁbrosing cholestatic
hepatitis achieved sustained viral response. These patients
Table 1.Baseline Demographic Characteristics
Characteristic
Cohort A: pretransplantation Cohort B: post-transplantation
Group 1
CTP B
Group 2
CTP C
Group 3
No cirrhosis
12 wk
(n ¼ 30)
24 wk
(n ¼ 29)
12 wk
(n ¼ 23)
24 wk
(n ¼ 26)
12 wk
(n ¼ 55)
24 wk
(n ¼ 56)
Median age, y (IQR) 60 (53–63) 58 (56–62) 58 (53–61) 59 (55–62) 59 (58–63) 58 (56–61)
Male, n (%) 22 (73) 18 (62) 14 (61) 18 (69) 45 (82) 46 (82)
Race, n (%)
White 29 (97) 26 (90) 21 (91) 24 (92) 50 (91) 49 (88)
Black 1 (3) 3 (10) 2 (9) 1 (4) 4 (7) 4 (7)
Other 0 0 0 1 (4) 1 (2) 3 (5)
HCV genotype
1a 19 (63) 22 (76) 15 (65) 18 (69) 40 (73) 40 (71)
1b 10 (33) 7 (24) 6 (26) 8 (31) 14 (25) 16 (29)
4 1 (3) 0 2 (9) 0 1 (2) 0
HCV-RNA level, log10 IU/mL ± SD 5.9 ± 0.7 5.8 ± 0.8 5.6 ± 0.6 5.8 ± 0.7 6.5 ± 0.6 6.4 ± 0.9
HCV-RNA level 800,000 IU/mL 16 (53) 18 (62) 9 (39) 11 (42) 45 (82) 46 (82)
IL28B genotype CC, n (%) 4 (13) 5 (17) 6 (26) 7 (27) 11 (20) 10 (18)
Previously treated 22 (73) 19 (66) 11 (48) 18 (69) 39 (71) 48 (86)
Regimen received
Peg/ribavirin 10 (45) 10 (53) 8 (73) 17 (94) 26 (67) 39 (81)
PI þ Peg/ribavirin 9 (41) 9 (47) 2 (18) 0 9 (23) 5 (10)
Other 3 (17) 0 1 (9) 1 (6) 4 (10) 4 (8)
Prior response
Nonresponse 15 (68) 14 (74) 7 (64) 13 (72) 23 (59) 33 (69)
Relapse/breakthrough 7 (32) 5 (26) 4 (36) 5 (28) 16 (41) 15 (31)
Median time since transplant, y – – – – 2.9 2.8
Median eGFR, mL/min (IQR) 98 (70–108) 81 (64–99) 77 (54–90) 78 (69–97) 61 (50–75) 71 (55–84)
Median platelets, (IQR) 88 (61–120) 73 (63–91) 81 (51–99) 71 (53–79) 143 (123–196) 152 (108–206)
Child–Turcotte–Pugh class
Class A (CTP score 5–6) 0 1 (3) 0 0 – –
Class B (CTP score 7–9) 27 (90) 27 (93) 7 (30) 4 (15) – –
Class C (CTP score 10–12) 3 (10) 1 (3) 16 (70) 22 (85) – –
MELD score
<10 6 (20) 8 (28) 0 0 – –
10–15 21 (70) 16 (55) 16 (70) 13 (50) – –
16–20 3 (10) 5 (17) 7 (30) 12 (46) – –
21–25 0 0 0 1 (4) – –
eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; Peg, pegylated; PI, protease inhibitor.
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LIVERalso showed large decreases in total bilirubin level by
treatment weeks 2–4, accompanied by suppression of HCV
RNA (Supplementary Appendix).
Patients With Genotype 4 HCV. Results for the 5
patients with genotype 4 HCV are included in the relevant
groups listed earlier, but we report them separately here.
Three of the 5 patients (1 patient each in groups 1, 2, and 3)
achieved SVR12, 1 patient in group 2 was lost to follow-up
evaluation after achieving SVR4, and 1 patient in group 5
died of complications relating to cirrhosis on day 75 of
treatment (Supplementary Appendix).
On-Study Liver Transplantation. Seven patients in
cohort A underwent liver transplantation, 4 patients before
the end of treatment and 3 patients in the follow-up period
before post-treatment week 12. Of the 7 patients, 6 patients
have achieved post-transplant virologic response. The sev-
enth patient had undetectable HCV-RNA level at post-transplantation week 2 and died 1 day later of multiorgan
failure and septic shock (Supplementary Appendix).
Post-Transplantation Immunosuppression. The
most commonly used immunosuppressive agents among the
229 patients in cohort B were tacrolimus in 174 patients
(76%); mycophenolate mofetil, mycophenolate sodium, or
mycophenolic acid in 82 patients (36%); and cyclosporine in
34 patients (15%) (Supplementary Appendix). One patient
experienced an increase in cyclosporine concentrations that
the investigator attributed to an interaction with study
treatment. However, increases in cyclosporine concentrations
also have been reported to be a result of an improvement of
organ function.Noother changes to immunosuppressionwere
reported as caused by drug interactions with the study
treatment. Forty instances of adjustments to immunosup-
pression in 24 patients were attributed by the investigators to
improvements in hepatic function after viral clearance.
Cohort B: post-transplantation
Group 4
CTP A
Group 5
CTP B
Group 6
CTP C
Group 7
FCH
12 wk
(n ¼ 26)
24 wk
(n ¼ 25)
12 wk
(n ¼ 26)
24 wk
(n ¼ 26)
12 wk
(n ¼ 5)
24 wk
(n ¼ 4)
12 wk
(n ¼ 4)
24 wk
(n ¼ 2)
60 (56–64) 61 (58–65) 61 (55–63) 61 58–65) 58 (58–62) 61 (60–62) 62 (59–65) 58 (52–64)
19 (73) 22 (88) 22 (85) 23 (88) 5 (100) 4 (100) 4 (100) 2 (100)
21 (81) 20 (80) 21 (81) 24 (92) 4 (80) 4 (100) 4 (100) 2 (100)
3 (12) 4 (16) 5 (19) 2 (8) 1 (20) 0 0 0
2 (8) 1 (4) 0 0 0 0 0 0
17 (65) 17 (68) 20 (77) 18 (69) 4 (80) 3 (75) 3 (75) 2 (100)
9 (35) 8 (32) 6 (23) 7 (27) 1 (20) 1 (25) 1 (25) 0
0 0 0 1 (4) 0 0 0 0
6.2 ± 0.8 6.7 ± 0.3 6.3 ± 0.6 6.2 ± 0.7 6.4 ± 0.4 6.3 ± 0.4 6.5 ± 1.2 7.1 ± 0.9
19 (73) 25 (100) 20 (77) 17 (65) 4 (80) 4 (100) 3 (75) 2 (100)
7 (27) 1 (4) 3 (12) 5 (19) 2 (40) 1 (25) 0 0
22 (85) 24 (96) 22 (85) 22 (85) 4 (80) 4 (100) 4 (100) 1 (50)
15 (68) 18 (75) 12 (55) 17 (77) 4 (100) 3 (75) 4 (100) 1 (100)
3 (14) 4 (17) 8 (36) 4 (18) 0 1 (25) 0 0
4 (18) 2 (8) 2 (9) 1 (5) 0 0 0 0
14 (64) 19 (79) 15 (68) 16 (73) 3 (75) 3 (75) 4 (100) 1 (100)
8 (36) 5 (21) 7 (32) 6 (27) 1 (25) 1 (25) 0 0
8.8 6.6 5.1 6.3 5.2 5.7 1.1 0.3
59 (55–67) 68 (57–88) 68 (53–77) 56 (51–65) 67 (54–67) 62 (47–69) 90 (36–92) 69 (n ¼ 1)
106 (75–138) 112 (88–168) 93 (73–121) 97 (66–97) 106 (63–160) 65 (54–93) 45 (42–131) 196 (182–210)
25 (96) 22 (88) 0 2 (8) 0 0 – –
1 (4) 3 (12) 24 (92) 24 (92) 2 (40) 1 (25) – –
0 0 2 (8) 0 3 (60) 3 (75) – –
15 (58) 13 (52) 8 (31) 5 (19) 1 (20) 0 – –
10 (38) 10 (40) 14 (54) 19 (73) 3 (60) 2 (50) – –
1 (4) 2 (8) 2 (8) 2 (8) 1 (20) 1 (25) – –
0 0 2 (8) 0 0 1 (25) – –
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treatment resistance analysis was conducted for 311 and
309 patients with genotype 1 HCV infection, respectively. A
total of 42 of 311 patients (14%) with genotype 1 HCV
infection had baseline NS5A resistance-associated variants
(RAVs), which confer reduced susceptibility to ledipasvir. Of
these 42 patients, 3 patients (7%) relapsed. The rate of
relapse among patients without baseline NS5A RAVs was
4% (10 of 269). None of the 25 patients with NS5A RAVs
who received ledipasvir-sofosbuvir plus ribavirin for 24
weeks relapsed. At virologic failure, 11 of 13 (85%) patients
who relapsed were observed to have NS5A variants: M28T,
Q30H/R, H58D, and Y93H/C. Neither S282T, the signature
RAV associated with resistance to sofosbuvir, nor other
nucleotide inhibitor RAVs were observed at pretreatment
or after treatment in any of the patients with virologic
failure.Safety
Given that the study population consisted of patients
with advanced liver disease, rates of adverse events were
high in all patient groups (Table 3). However, only 13 pa-
tients (4%) discontinued ledipasvir-sofosbuvir prematurely
secondary to adverse events. The only adverse events that
led to discontinuation in more than 1 patient were sepsis
(n ¼ 2), acute renal failure (n ¼ 2), dyspnea (n ¼ 2), and
gastrointestinal hemorrhage (n ¼ 2). Seventy-seven patients
(23%) experienced serious adverse events, the majority of
which were associated with hepatic decompensation. A full
list of serious adverse events is provided in Supplementary
Table 7. Thirteen patients died during the study: 4 patients
during treatment, 6 patients after discontinuing study
treatment but within 30 days after treatment, and 3 patients
at more than 30 days after the end of treatment. The most
common cause of death was septic shock accompanied by
Table 2.Response During and After Treatment
Response
Cohort A: pretransplantation Cohort B: post-transplantation
Group 1
CTP B
Group 2
CTP C
Group 3
No cirrhosis
Group 4
CTP A
Group 5
CTP B
Group 6
CTP C
Group 7
FCH
12 wk
(n ¼ 30)
24 wk
(n ¼ 29)
12 wk
(n ¼ 23)
24 wk
(n ¼ 26)
12 wk
(n ¼ 55)
24 wk
(n ¼ 56)
12 wk
(n ¼ 26)
24 wk
(n ¼ 25)
12 wk
(n ¼ 26)
24 wk
(n ¼ 26)
12 wk
(n ¼ 5)
24 wk
(n ¼ 4)
12 wk
(n ¼ 4)
24 wk
(n ¼ 2)
HCV RNA
<LLOQ on
treatment
At week 2 11/30 (37) 12/29 (41) 9/23 (39) 10/26 (38) 27/55 (49) 23/55 (42) 9/26 (35) 7/25 (28) 2/25 (8) 11/26 (42) 2/5 (40) 1/4 (25) 2/4 (50) 0/2
At week 4 25/30 (83) 24/29 (83) 23/23 (100) 22/26 (85) 48/55 (87) 50/55 (91) 23/26 (88) 20/25 (80) 18/25 (72) 23/26 (88) 5/5 (100) 4/4 (100) 4/4 (100) 1/2 (50)
At week 6 30/30 (100) 29/29 (100) 22/22 (100) 25/26 (96) 53/55 (96) 55/55 (100) 25/25 (100) 25/25 (100) 25/25 (100) 26/26 (100) 5/5 (100) 4/4 (100) 4/4 (100) 1/2 (50)
HCV RNA
<LLOQ after
treatment
At week 4
(SVR4)
27/30 (90) 24/27 (89) 20/22a (91) 22/23 (96) 53/55 (96) 55/56 (98) 25/26 (96) 25/25 (100) 23/26 (88) 24/26 (92) 5/5 (100) 3/4 (75) 4/4 (100) 2/2 (100)
At week 12
(SVR12)
26/30 (87) 24/27 (89) 19/22 (86) 20/23 (87) 53/55 (96) 55/56 (98) 25/26 (96) 24/25 (96) 22/26 (85) 23/26 (88) 3/5 (60) 3/4 (75) 4/4 (100) 2/2 (100)
90% CI 72–95 74–97 68–96 70–96 89–99 92–100 83–100 82–100 68–95 73–97 19–92 25–99 47–100 22–100
Virologic failure
Breakthrough 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Relapse 3 1 1 2 2 0 0 0 1 0 2 1 0 0
CI, conﬁdence interval; LLOQ, lower limit of quantiﬁcation.
aPatients undergoing transplantation with HCV-RNA levels less than the LLOQ before the post-treatment visit window were excluded from analysis.
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Figure 1. Patient disposition during the study. AE, adverse event; LDV, ledipasvir; SOF, sofosbuvir; LT, liver transplantation;
RBV, ribavirin.
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Rmultiorgan failure (Supplementary Appendix). None of the
deaths were deemed treatment-related.
Across all groups, the most common grade 3 or 4 labo-
ratory abnormalities were decreases in hemoglobin and
lymphocyte levels and increases in total bilirubin and
glucose level. Decreases in hemoglobin level and hyper-
bilirubinemia are known to be associated with ribavirin-
induced hemolysis.
The most common grade 3 or 4 laboratory abnormality
for cohort A was increases in total bilirubin level followed
by lymphopenia. For cohort B patients, the most common
grade 3 or 4 laboratory abnormalities were decreases in
hemoglobin and lymphocyte levels. Increases in serum
glucose level were observed mostly among patients with
increased serum glucose level at baseline. Across all groups,
median creatinine values remained stable while on
treatment.
A total of 132 (39%) and 44 (13%) patients experienced
hemoglobin values less than 10 and 8.5, respectively. Fifty-
one (15%) patients received at least 1 concomitant blood
product or erythropoietin. The average daily dose of riba-
virin in patients with decompensated cirrhosis (pre-
transplantation or post-transplantation) was approximately
600 mg. The average daily dose of ribavirin in patients with
no cirrhosis or compensated cirrhosis was approximately
1000 mg. The dose of ribavirin was reduced in 43% of pa-
tients (144 of 337) and discontinued altogether in 18% of
patients (59 of 337). Discontinuation of ribavirin was more
common in the 24-week groups and among patients with a
worsening disease state (Supplementary Appendix).
There were 3 reports of acute cellular rejection in post-
transplant patients. None of the 3 cases were thought to be
related to study treatment. Two reports were in group 3, 1on day 169 of treatment, which subsequently resolved, and
1 at 91 days after the last dose of study drug, which has not
resolved. One patient in group 1 with acute cellular rejection
underwent transplantation during the study and had graft
loss 6 days after transplant. This patient was retransplanted
9 days later, and went on to achieve post-transplant viro-
logic response.Discussion
In this large-scale trial that evaluated the efﬁcacy of all-
oral direct-acting antiviral therapy in patients with HCV
genotype 1 and decompensated cirrhosis, and post-
transplant patients with cirrhosis, 12 or 24 weeks of
treatment with ledipasvir-sofosbuvir and ribavirin resulted
in high rates of response. Rates of sustained virologic
response were greater than 85% in every group of patients
with Child–Pugh class B decompensated cirrhosis—in pa-
tients who had and had not undergone liver transplantation,
as well as in patients who were receiving 12 and 24 weeks
of treatment. Similar response rates were observed in
Child–Pugh class C patients who had not undergone liver
transplantation. Rates of response were numerically lower
in liver transplant recipients with Child–Pugh class C dis-
ease, but the small sample size (n ¼ 9) make this a pre-
liminary observation. Our results also show that SVR12 in
patients with decompensated cirrhosis is associated with
early improvements in CPT and MELD scores, suggesting
that eradication of the virus can improve hepatic function
rapidly by attenuating the injury and inﬂammation caused
by HCV replication. Similar effects have been described for
suppression of hepatitis B virus in patients with decom-
pensated disease.14,15 Long-term follow-up evaluation of
Figure 2. Change from
baseline to post-treatment
week 4 in MELD scores in
patients with Child–Pugh B
and C disease. The ﬁgure
shows the change from
baseline in MELD scores in
patients in groups 1, 2, 5,
and 6. MELD is a scoring
system for assessing the
severity of chronic liver
disease and was designed
to measure the urgency of
the need for liver trans-
plantation. The scores
were calculated using the
patient’s values for serum
bilirubin, serum creatinine,
and the international
normalized ratio for pro-
thrombin time. The result-
ing scores range from 6
(the least ill patients) to
40þ (gravely ill patients).
The 3-month mortality rate
was 71% for patients with
a score of 40 or higher,
53% for patients with a
score of 30–39, 20% for
patients with a score of
20–29, 6% for patients
with a score of 10–19, and
2% for patients with a
score of 9 or less.26 Each
black bar represents an
individual patient. Missing
patient data for the post-
treatment week 4 visit are
indicated in the ﬁgure.
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LIVERpatients with Child–Pugh class B and C disease who have
achieved sustained virologic response is needed to deter-
mine possible long-term beneﬁts, such as decreased de-
mand for liver transplantation, reduced liver-related
mortality, and hepatocellular carcinoma, as well as revers-
ibility of clinical liver failure.
Our study included a small number of patients with FCH,
an uncommon complication of liver transplantation char-
acterized by highly aggressive progression of cholestasis
and ﬁbrosis. Until recently, there was no effective treatment
for this frequently fatal condition. A number of recent case
reports have shown that FCH can be treated successfullywith direct-acting antiviral therapy.16–19 Our results—all 6
patients with FCH treated with ledipasvir-sofosbuvir plus
ribavirin achieved sustained virologic response—provide
further encouraging evidence that FCH now may be a
manageable complication of liver transplantation.
Among patients in groups 3 and 4, which represented a
broad spectrum of patients post-transplant, from mild his-
tologic disease to compensated cirrhosis, rates of sustained
virologic response ranged from 96% to 98%. These rates
are generally in keeping with those observed in the ION-1
and ION-2 trials, in which patients who had not undergone
liver transplantation received ledipasvir-sofosbuvir for
Table 3.Rates of Serious Adverse Events and Adverse Events Leading to Study Drug Discontinuation
Characteristic
Cohort A: pretransplantation Cohort B: post-transplantation
CTP B CTP C No cirrhosis CTP A CTP B CTP C FCH
12 wk
(n ¼ 30)
24 wk
(n ¼ 29)
12 wk
(n ¼ 23)
24 wk
(n ¼ 26)
12 wk
(n ¼ 55)
24 wk
(n ¼ 56)
12 wk
(n ¼ 26)
24 wk
(n ¼ 25)
12 wk
(n ¼ 26)
24 wk
(n ¼ 26)
12 wk
(n ¼ 5)
24 wk
(n ¼ 4)
12 wk
(n ¼ 4)
24 wk
(n ¼ 2)
Any adverse event,
n (%)
29 (97) 28 (97) 23 (100) 26 (100) 55 (100) 55 (98) 25 (96) 24 (96) 25 (96) 26 (100) 5 (100) 4 (100) 4 (100) 2 (100)
Serious adverse
event, n (%)
3 (10) 10 (34) 6 (26) 11 (42) 6 (11) 12 (21) 3 (12) 4 (16) 5 (19) 11 (42) 1 (20) 3 (75) 1 (25) 1 (50)
Discontinuation of
LDV-SOF owing to,
n (%)
0 2 (7) 1 (4) 2 (8) 0 2 (4) 1 (4) 0 2 (8) 3 (12) 0 0 0 0
Sepsis 0 2 (7) 0 0 0 0 0 0 0 0 0 0 0 0
Gastric hemorrhage 0 1 (3) 0 0 0 0 0 0 1 (4) 0 0 0 0 0
Acute renal failure 0 0 0 1 (4) 0 0 0 0 0 1 (4) 0 0 0 0
ALT level increased 0 0 0 0 0 1 (2) 0 0 0 0 0 0 0 0
AST level increased 0 0 0 0 0 1 (2) 0 0 0 0 0 0 0 0
Aortic dissection 0 0 0 0 0 0 0 0 0 1 (4) 0 0 0 0
Chest pain 0 0 0 0 0 0 0 0 1 (4) 0 0 0 0 0
Convulsion 0 0 0 0 0 0 0 0 0 1 (4) 0 0 0 0
Diarrhea 0 0 0 0 0 0 0 0 1 (4) 0 0 0 0 0
Dyspnea 0 0 0 0 0 1 (2) 1 (4) 0 0 0 0 0 0 0
Infection 0 0 1 (4) 0 0 0 0 0 0 0 0 0 0 0
Hepatic
encephalopathy
0 0 0 1 (4) 0 0 0 0 0 0 0 0 0 0
Hepatic hydrothorax 0 0 1 (4) 0 0 0 0 0 0 0 0 0 0 0
Hypotension 0 0 0 1 (4) 0 0 0 0 0 0 0 0 0 0
Peritoneal
hemorrhage
0 0 0 0 0 0 0 0 0 1 (4) 0 0 0 0
Shock 0 0 0 0 0 0 0 0 0 1 (4) 0 0 0 0
Vomiting 0 0 0 0 0 0 0 0 1 (4) 0 0 0 0 0
ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDV-SOF, ledipasvir-sofosbuvir.
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LIVER12 or 24 weeks with and without ribavirin.20,21 The CORAL-
1, a study that evaluated the combination of ombitasvir-
paritaprevir/ritonavir-dasabuvir plus ribavirin for 24
weeks in patients with mild histologic recurrent HCV pro-
vided comparable efﬁcacy for liver transplant recipients
(ﬁbrosis stages, 0–2).22 However, the efﬁcacy of this com-
bination in patients with more severe liver disease is un-
known because CORAL-1 did not include patients with
hepatic decompensation or more advanced stages of
recurrence (ﬁbrosis stages 3 and 4).
An important attribute of ledipasvir-sofosbuvir is the
lack of clinically relevant drug–drug interactions with
CYP3A4 substrates such as calcineurin and mammalian
target of rapamycin inhibitors. Although sofosbuvir and
ledipasvir do not have signiﬁcant direct effects on the
metabolism of immunosuppressive agents,23 HCV infection
itself is known to affect dosing requirements of calcineurin
inhibitors. In addition, eradication of HCV is likely to
reverse, at least in part, the inhibitory effects of HCV pro-
teins on adaptive immunity. For these reasons, we recom-
mend close monitoring of immunosuppression trough levels
during and after treatment of HCV infection.
This study was designed to evaluate 2 durations of
ledipasvir-sofosbuvir plus ribavirin. Because patients in all
treatment arms received the same combination, the
importance of ribavirin in the regimen cannot be deter-
mined. Although ribavirin dosing was reduced in many
patients with decompensated disease, there are not
adequate data to determine whether relapse was associated
with decreased ribavirin exposure. Patients with decom-
pensated liver disease experience high frequencies of
ribavirin hemotoxicity. For this reason, we used lower
initial daily dosing in patients with Child–Pugh class C
cirrhosis. Whether higher doses of ribavirin would be
associated with enhanced SVR rates in participants with
Child–Pugh class C cirrhosis would be an interesting subject
of future studies.
The beneﬁts of treating patients before the onset of
decompensation have been shown clearly, with several-fold
decreases in the risk of death, need for liver transplantation,
and development of hepatocellular carcinoma.24,25 Whether
similar beneﬁts in outcomes will accrue to patients with
Child–Pugh class B and C cirrhosis who are cured of HCV
infection remains to be seen. The optimal timing of treat-
ment in patients with Child–Pugh class B and C cirrhosis
among patients considering liver transplantation requires
further investigation. Current treatment decisions should be
made in collaboration with the transplant center caring for
the patient. In the post-transplant setting our results again
suggest that treating before the development of decom-
pensation results in a numerically higher SVR and patients
again will have to be followed up to determine the potential
for long-term beneﬁts on graft survival and post-
transplantation mortality.
In conclusion, our ﬁndings show that ledipasvir-
sofosbuvir plus ribavirin for 12 weeks is an effective
treatment for a group of patients currently without effective
treatment options—patients with advanced liver disease,
including patients with decompensated liver function beforeand after liver transplantation. Extending treatment to 24
weeks did not appear to be associated with improved
outcomes.
SOLAR-1 Study Team Members
The SOLAR-1 study team members included the
following: Princy Kumar, Eugene Schiff, Nezam Afdhal,
Robert S. Brown, Michael Fried, Kris Kowdley, Norah
Terrault, Michael Charlton, Paul Kwo, Steve Flamm, John
Lake, Greg Everson, Mark Sulkowski, Michael Curry,
Rajender Reddy, Lewis Teperman, Hugo Vargas, Surakit
Pungpapong, Andrew Muir, Atif Zaman, Kimberly Brown,
Charles Landis, Alexander Kuo, Robert Fontana, Jacqueline
O’Leary, Richard Gilroy, Obaid Shaikh, Kevin Korenblat,
Richard Stravitz, Kymberly Watt, Narayanan Menon, James
Bredfeldt, and Carlos Romero-Marrero.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2015.05.010.References
1. Fink SA, Jacobson IM. Managing patients with hepatitis-B-
related or hepatitis-C-related decompensated cirrhosis.
Nat Rev Gastroenterol Hepatol 2011;8:285–295.
2. Berry PA, Thomson SJ. The patient presenting with
decompensated cirrhosis. Acute Med 2013;12:232–238.
3. Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR
2012 annual data report: liver. Am J Transplant 2014;
14(Suppl 1):69–96.
4. Adam R, McMaster P, O’Grady JG, et al. Evolution of liver
transplantation in Europe: report of the European Liver
Transplant Registry. Liver Transpl 2003;9:1231–1243.
5. Charlton M, Ruppert K, Belle SH, et al. Long-term results
and modeling to predict outcomes in recipients with HCV
infection: results of the NIDDK liver transplantation
database. Liver Transpl 2004;10:1120–1130.
6. Berenguer M, Prieto M, Rayon JM, et al. Natural history
of clinically compensated hepatitis C virus-related graft
cirrhosis after liver transplantation. Hepatology 2000;
32:852–858.
7. Forman LM, Lewis JD, Berlin JA, et al. The association
between hepatitis C infection and survival after ortho-
topic liver transplantation. Gastroenterology 2002;
122:889–896.
8. Sovaldi (sofosbuvir) tablets; US prescribing information.
Foster City, CA: Gilead Sciences, 2013. Available from:
https://www.gilead.com/w/media/Files/pdfs/medicines/
liver-disease/sovaldi/sovaldi_pi.pdf.
9. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and
ribavirin prevent recurrence of HCV infection after liver
transplantation: an open-label study. Gastroenterology
2015;148:100–107.
10. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and
ribavirin for treatment of compensated recurrent hepatitis
September 2015 Ledipasvir and Sofosbuvir in Liver Disease 659
CL
IN
IC
AL
LI
VE
RC virus infection after liver transplantation. Gastroenter-
ology 2015;148:108–117.
11. Forns X, Charlton M, Denning J, et al. Sofosbuvir
compassionate use program for patients with severe
recurrent hepatitis C following liver transplantation.
Hepatology 2015;61:1485–1494.
12. Harvoni (ledipasvir and sofosbuvir) tablets: US prescrib-
ing information. Foster City, CA: Gilead Sciences, 2014.
Available from: http://www.gilead.com/w/media/Files/
pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf.
13. Bourlière M, Bronowicki J-P, de Ledinghen V, et al.
Ledipasvir and sofosbuvir for 12 weeks with ribavirin
or for 24 weeks alone in patients with genotype 1
HCV infection and cirrhosis in whom prior protease
inhibitor therapy failed (SIRIUS): a randomized,
double-blind, phase 2 trial. Lancet Infect Dis 2015;
15:397–404.
14. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil
for wait-listed and post-liver transplantation patients with
lamivudine-resistant hepatitis B: ﬁnal long-term results.
Liver Transpl 2007;13:349–360.
15. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil
therapy for lamivudine-resistant hepatitis B in pre- and
post-liver transplantation patients. Hepatology 2003;
38:1419–1427.
16. Delabaudière C, Lavayssière L, Dörr G, et al. Successful
treatment of ﬁbrosing cholestatic hepatitis with pegylated
interferon, ribavirin and sofosbuvir after a combined
kidney-liver transplantation. Transpl Int 2015;28:255–258.
17. Borentain P, Colson P, Dhiver C, et al. Successful
treatment with sofosbuvir of ﬁbrosing cholestatic hepa-
titis C after liver transplantation in HIV-HCV coinfected
patient. Antivir Ther 2015;20:252–356.
18. Kim B, Trivedi A, Thung SN, et al. Case report of suc-
cessful treatment of ﬁbrosing cholestatic hepatitis C with
sofosbuvir and ribavirin after liver transplantation. Semin
Liver Dis 2014;34:108–112.
19. Al Nahdi N, Ford JA, Greanya ED, et al. First successful
treatment of post-liver transplant hepatitis C ﬁbrosing
cholestatic hepatitis with boceprevir, peginterferon and
ribavirin in a pre-transplant null responder. Ann Hepatol
2013;12:156–160.
20. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and
sofosbuvir for untreated HCV genotype 1 infection.
N Engl J Med 2014;370:1889–1898.
21. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and
sofosbuvir for previously treated HCV genotype 1 infec-
tion. N Engl J Med 2014;370:1483–1493.
22. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free
antiviral regimen for HCV after liver transplantation.
N Engl J Med 2014;371:2375–2382.
23. Trotter JF, Osborne JC, Heller M, et al. Effect of hepatitis
C infection on tacrolimus doses and blood levels in liver
transplantation recipients. Aliment Pharmacol Ther 2005;
22:37–44.
24. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sus-
tained virological responders with histologically advanced
chronic hepatitis C. Hepatology 2010;52:833–844.
25. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained
virologic response and clinical outcomes in patients withchronic hepatitis C and advanced ﬁbrosis. Ann Intern
Med 2007;147:677–684.
26. Wiesner R, Edwards E, Freeman R, et al. Model for end-
stage liver disease (MELD) and allocation of donor livers.
Gastroenterology 2003;124:91–96.
Received April 30, 2015. Accepted May 8, 2015.
Reprint requests
Address requests for reprints to: Michael Charlton, MD, Intermountain Medical
Center, 5169 S Cottonwood Street, Murray, Utah 84107. e-mail:
michael.charlton@imail.org; fax: (801) 507-8343; or Nezam Afdhal, MD, Beth
Israel Deaconess Medical Center, 110 Francis Street, Boston, Massachusetts
02215. e-mail: nafdhal@bidmc.harvard.edu; fax: (617) 632-1065.
Acknowledgments
Presented in part at the annual meeting of the American Association for the
Study of Liver Diseases; Boston, MA; November 7–11, 2014.
The authors thank the patients and their families, as well as the investigators
and study-site personnel; Sherri Paxton and Ravi Grewal (Gilead Sciences) for
contributions to the conduct of the study; and David McNeel (Gilead Sciences)
for providing editorial assistance.
Conﬂicts of interest
These authors disclose the following: Michael Charlton has received research
support and grants from Gilead; Gregory Everson has received research
support and grants from AbbVie, BMS, Eisai, Gilead, Janssen, Merck, and
Roche/Genentech, and has served on advisory boards for AbbVie, BMS,
Gilead, Janssen, and Merck; Princy Kumar has served as a consultant for
Janssen and ViiV Healthcare, and is a stock shareholder of GSK, Gilead,
J&J, Merck, and Pﬁzer; Charles Landis has received research support and
grants from AbbVie, BMS, and Gilead; Robert Brown Jr has received
research support and grants from Gilead, and has served as a consultant for
Gilead; Norah Terrault has received research support and grants from Gilead;
Jacqueline O’Leary has served as a consultant for AbbVie, Janssen, and
Gilead, and was on the speakers bureau for AbbVie and Gilead; Hugo
Vargas has received research support and grants from AbbVie, BMS, Eisai,
Gilead, and Merck; Alexander Kuo has received research support and grants
from Gilead, and has served as a consultant for AbbVie; Eugene Schiff has
received research support and grants from Abbot, BMS, Beckman Coulter,
Conatus, Discovery Life Sciences, Gilead, MedMira, Merck, Orasure
Technologies, Roche Molecular, Janssen, and Siemens, has received
personal fees from Acorda, Arrowhead, BMS, Gilead, Merck, Janssen, Pﬁzer,
and Salix, and has received nonﬁnancial support from Merck and Salix; Mark
Sulkowski has received research support and grants from AbbVie, BMS,
Gilead, Janssen, and Merck, has served as a consultant for AbbVie, BMS,
Gilead, Janssen, and Merck, has served on an advisory board for Gilead,
and has been involved with the National Institutes of Health; Richard Gilroy
has received research support and grants from Gilead, and has received
personal fees from AbbVie, Gilead, NPS, and Salix; Kymberly Watt has
served as a sponsor for Gilead; Kimberly Brown has received research
support and grants from AbbVie, BMS, Centers for Disease Control
Foundation, Gilead, Hyperion, Janssen, and Vertex, has served as a
consultant for AbbVie, BMS, Gilead, Janssen, and Merck, has served on the
speakers bureau for AbbVie, CLDF, Gilead, HCV Viewpoints, and Simply
Speaking, has served on advisory boards for AJT Images, AST Past, CLDF,
and CLD Journal, and was involved with Medscape; Paul Kwo has received
research support and grants from AbbVie, BMS, Conatus, Gilead, Janssen,
Merck, Roche, and Vertex, has served as a consultant for Gilead, has served
on advisory boards for AbbVie, BMS, Gilead, Janssen, Merck, Novartis, and
Vertex, and was on the speakers’ bureau for Merck and Vertex; Surakit
Pungpapong has received research support and grants from BMS and
Gilead; Andrew Muir has received research support and grants from Gilead,
and has served on advisory boards for Gilead; Robert Fontana has received
research support and grants from BMS, Gilead, Janssen, and Vertex; K.
Rajender Reddy has received research support and grants from AbbVie,
BMS, Genentech-Roche, Gilead, Janssen, Merck, and Vertex, has served as
a consultant for AbbVie, BMS, Genentech-Roche, Gilead, Idenix, Janssen,
Merck, and Vertex, has served on advisory boards for CLDF and Novartis,
and has received payment for the development of educational presentations
from ViralEd; Nezam Afdhal has received research support and grants from
AbbVie, BMS, and Gilead, has served on advisory boards for Gilead, has
served as a consultant for Gilead, and has received personal fees from
AbbVie, Achillion, BMS, Merck, Janssen, and SprinBank; and Jill Denning,
Sarah Arterburn, Theo Brandt-Sarif, Phillip Pang, and John McHutchison are
employees of Gilead. The remaining authors disclose no conﬂicts.
Funding
Supported by Gilead Sciences. Gilead Sciences collected the data, monitored
the study conduct, and performed the statistical analyses.
